Choroidal drainage good option for acute angle closure

Article

Choroidal drainage can be a safe and effective interventional procedure for patients presenting with acute angle closure secondary to Topiramate toxicity.

Choroidal drainage can be a safe and effective interventional procedure for patients presenting with acute angle closure secondary to Topiramate toxicity, according to a case report published in the December 2007 issue of the Journal of Glaucoma.

Topiramate is an anti-convulsant drug administered to treat certain types of seizures in patients with epilepsy.

Rajul Parikh and co-workers from the Christian Medical College, Vellore and the LV Prasad Eye Institute, Hyderabad, India reported the role of choroidal drainage in a patient with acute bilateral angle closure secondary to cilio-choroidal effusion with Topiramate.

Two-weeks after commencing Topiramate for the management of epilepsy, the patient developed acute bilateral angle closure secondary to cilio-choroidal effusion with lenticulo-corneal touches for which choroidal drainage was performed.

Following the procedure, the anterior chamber deepened, the corneal oedema resolved, choroidals began to resolve and intraocular pressure was controlled without medication. The researchers therefore concluded that, in patients presenting with acute angle closure secondary to Topiramate toxicity, choroidal drainage is a safe and effective interventional procedure.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.